SCHEMBL3626089

SCHEMBL3626089

CC(C)CCCC(Cl)Cl

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28491812 0.93 LMNA (0.53)
SCHEMBL28988373 0.90 LMNA (0.50)
SCHEMBL6165852 0.90 LMNA (0.50)
Alcohol SCHEMBL14150364 0.89 LMNA (0.43)
Ether SCHEMBL1582237 0.84 LMNA (0.40)
SCHEMBL42290 0.82
SCHEMBL2566012 0.82
SCHEMBL16469538 0.82
SCHEMBL9634213 0.80
SCHEMBL28497585 0.79

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-109134716-B Vanadium catalyst and method for preparing olefin polymer 北京引发科技有限公司 2020-11-10 CN claimed
CN-109134716-B Vanadium catalyst and method for preparing olefin polymer 北京引发科技有限公司 2020-11-10 CN disclosed
EP-2532664-A1 Substituted indolo [2,3-a] quinolizines in the treatment of cancer Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) 2012-12-12 EP disclosed
EP-2046741-B1 INDOLES AS 5-HT6 MODULATORS PROXIMAGEN LTD (GB) 2012-10-31 EP disclosed
US-7812017-B2 4-substituted indole and indoline compounds BIOVITRUM AB (PUBL.) (SE) 2010-10-12 US disclosed
US-20090143354-A1 P2X7 Receptor Antagonists and Their Use ASTRAZENECA AB (SE) 2009-06-04 US disclosed
US-20080261977-A1 Pyrimidine Derivatives as Cannabinoid Receptor Modulators GLAXO GROUP LIMITED (GB) 2008-10-23 US disclosed
US-7439240-B2 Purine-or pyrrolol[2,3-d]pyrimidine-2-carbonitiles for treating diseases associated with cysteine protease activity ASTRAZENECA AB (SE) 2008-10-21 US disclosed
EP-1328515-B1 INDOLINE DERIVATIVES AND THEIR USE AS 5-HT2 RECEPTOR LIGANDS HOFFMANN LA ROCHE (CH) 2008-08-06 EP disclosed
US-7408065-B2 P2X7 receptor antagonists and their use ASTRAZENECA AB (SE) 2008-08-05 US disclosed
EP-1196783-A2 SCREENING FOR THERAPEUTIC AGENTS BEING SCAP ANTAGONISTS GLAXO GROUP LIMITED (GB) 2002-04-17 EP disclosed
US-6342601-B1 TREATING ALLOGRAFT REJECTION, RHEUMATOID ARTHRITIS ASTRAZENECA AB (SE) 2002-01-29 US disclosed
US-6300352-B1 FOR THERAPY OF ASTHMA ASTRAZENECA AB (SE) 2001-10-09 US disclosed
WO-2001012603-A1 INDOLE DERIVATIVES, PROCESS FOR THEIR PREPARATION, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR MEDICINAL APPLICATION VERNALIS RESEARCH LIMITED (GB) 2001-02-22 WO disclosed
CN-1284079-A Novel compounds ASTRA ZENECA BRITISH LTD (GB) 2001-02-14 CN disclosed
WO-2001006261-A2 SCREENING FOR THERAPEUTIC AGENTS BEING SCAP ANTAGONISTS GLAXO GROUP LIMITED (GB) 2001-01-25 WO disclosed
US-6143751-A Pyridine derivatives and pharmaceutical compositions containing them ASTRAZENECA UK LIMITED (GB) 2000-11-07 US disclosed
EP-1036076-A1 NOVEL COMPOUNDS AstraZeneca UK Limited (GB) 2000-09-20 EP disclosed
WO-1999029695-A1 NOVEL COMPOUNDS ASTRAZENECA UK LIMITED (GB) 1999-06-17 WO disclosed
US-3950385-A Preparation of nitronitrates TEXACO INC. (US) 1976-04-13 US disclosed